Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Article

关键词: CHRONIC MYELOID-LEUKEMIA;    TYROSINE KINASE;    CD34(+) CELLS;    CANCER;    INHIBITION;    EXPRESSION;    IMATINIB;    TUMOR;    COMBINATION;    MICROARRAY;   

DOI  :  10.1038/nature18288

来源: SCIE

【 摘 要 】

Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR-ABL. Direct inhibition of BCR-ABL kinase has revolutionized disease management, but fails to eradicate leukaemic stem cells (LSCs), which maintain CML. LSCs are independent of BCR-ABL for survival, providing a rationale for identifying and targeting kinase-independent pathways. Here we show-using proteomics, transcriptomics and network analyses-that in human LSCs, aberrantly expressed proteins, in both imatinib-responder and non-responder patients, are modulated in concert with p53 (also known as TP53) and c-MYC regulation. Perturbation of both p53 and c-MYC, and not BCR-ABL itself, leads to synergistic cell kill, differentiation, and near elimination of transplantable human LSCs in mice, while sparing normal HSCs. This unbiased systems approach targeting connected nodes exemplifies a novel precision medicine strategy providing evidence that LSCs can be eradicated.

【 授权许可】

Free